{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive matching placebo administered as intravenous (IV) infusions.",
            "Participants will receive a total dose of Prochymal\u00ae 600 x 10^6 cells, IV infusion, on four days, once daily.",
            "Participants will receive a total dose of Prochymal\u00ae 1200 x 10^6 cells, IV infusion, on four days, once daily."
      ],
      "ArmGroupInterventionName": [
            "Drug: Placebo",
            "Drug: Prochymal\u00ae",
            "Drug: Prochymal\u00ae"
      ],
      "ArmGroupLabel": [
            "Placebo",
            "Prochymal\u00ae - Low dose",
            "Prochymal\u00ae - High dose"
      ],
      "ArmGroupType": [
            "Placebo Comparator",
            "Active Comparator",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00482092"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The protocol investigates the safety and efficacy of using PROCHYMAL\u00ae adult human stem cells to induce remission. PROCHYMAL is delivered through a vein in the arm four times over two weeks, for approximately an hour each time."
      ],
      "BriefTitle": [
            "Evaluation of PROCHYMAL\u00ae Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "September 15, 2014"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Crohn's Disease"
      ],
      "ConditionAncestorId": [
            "D000015212",
            "D000005759",
            "D000005767",
            "D000004066",
            "D000007410"
      ],
      "ConditionAncestorTerm": [
            "Inflammatory Bowel Diseases",
            "Gastroenteritis",
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Intestinal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC06",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Digestive System Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Crohn's Disease"
      ],
      "ConditionBrowseLeafId": [
            "M5790",
            "M17069",
            "M9596",
            "M8027",
            "M8035",
            "M6407"
      ],
      "ConditionBrowseLeafName": [
            "Crohn Disease",
            "Inflammatory Bowel Diseases",
            "Intestinal Diseases",
            "Gastroenteritis",
            "Gastrointestinal Diseases",
            "Digestive System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003424"
      ],
      "ConditionMeshTerm": [
            "Crohn Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "A significant number of individuals with Crohn's disease do not find relief with existing steroidal, immunosuppressive, or biologic therapies, and are forced to seek surgery or other drastic measures for treatment.\n\nPROCHYMAL\u00ae adult human stem cells are manufactured from healthy, volunteer donors, extensively tested, and are stored to be available as needed. Human and animal studies have shown that the cells do not require any donor-recipient matching. The cells may have both immunosuppressive and healing benefits in Crohn's disease. The cells naturally migrate specifically to sites of inflammation, so their effects are believed to be local and self-limiting rather than systemic.\n\nProtocol 603 is enrolling subjects to evaluate the ability of PROCHYMAL to induce remission in subjects with moderate-to-severe disease (Crohn's disease activity index -- CDAI -- of between 250 and 450, inclusive) who have failed or been intolerant of at least one drug in each of the steroid, immunosuppressant, and biologic classes."
      ],
      "DispFirstPostDate": [
            "December 23, 2021"
      ],
      "DispFirstPostDateType": [
            "Actual"
      ],
      "DispFirstSubmitDate": [
            "December 20, 2021"
      ],
      "DispFirstSubmitQCDate": [
            "December 20, 2021"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nfailed (within last 2 yr) or intolerant of at least one steroid AND at least one immunosuppressant AND at EXACTLY one biologic\nCDAI between 250 and 450, inclusive\nendoscopically or radiographically confirmed Crohn's disease of ileus or colon or both\nC-Reactive Protein Test (CRP) of at least 5 mg/l (0.5 mg/dl)*OR* CDAI of at least 300\nweight between 40 and 150 kg, inclusive\nadequate renal function\nnegative tuberculosis skin (PPD) test (or evaluated low risk of TB activation)\n\nExclusion Criteria:\n\nHIV or hepatitis infection active\nallergy to CT contrast agents, or to bovine or porcine products\nsymptomatic fibrostenotic Crohn's disease\npermanent ostomy\nbiologic therapy within past 90 d\nprednisone greater than 20 mg/d within past month\nshort-bowel syndrome\ntotal parenteral nutrition\nabnormal liver function\nmalignancy active within past 5 years (except completely resected basal or squamous cell carcinoma of skin)\nenteric pathogens, including C. difficile\nhistory of colonic mucosal dysplasia\ncurrent or prior evidence of tuberculosis (TB) (unless risk of activation or re-activation deemed low)"
      ],
      "EnrollmentCount": [
            "330"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000000998",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Prochymal\u00ae - High dose",
            "Prochymal\u00ae - Low dose",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "Infl",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Anti-Inflammatory Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Cardia"
      ],
      "InterventionBrowseLeafId": [
            "M186752",
            "M3369",
            "M3466",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Prochymal\u00ae IV infusion",
            "Prochymal\u00ae Placebo-matching IV infusion"
      ],
      "InterventionMeshId": [
            "C000711674"
      ],
      "InterventionMeshTerm": [
            "Remestemcel-l"
      ],
      "InterventionName": [
            "Prochymal\u00ae",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Adult Human Mesenchymal Stem Cells"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Crohn's disease",
            "adult stem cell therapy"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 13, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 11, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Los Angeles",
            "San Francisco",
            "Wheat Ridge",
            "Clearwater",
            "Jacksonville",
            "Winter Park",
            "Atlanta",
            "Chicago",
            "Urbana",
            "Indianapolis",
            "Topeka",
            "Lexington",
            "Louisville",
            "Baton Rouge",
            "Baltimore",
            "Bethesda",
            "Chevy Chase",
            "Boston",
            "Boston",
            "Worcester",
            "Dearborn",
            "Troy",
            "Minneapolis",
            "Saint Louis",
            "Lebanon",
            "New York",
            "New York",
            "Rochester",
            "Rochester",
            "Stony Brook",
            "Charlotte",
            "Pinehurst",
            "Winston-Salem",
            "Tulsa",
            "Tulsa",
            "Pittsburgh",
            "Pittsburgh",
            "Germantown",
            "Nashville",
            "Nashville",
            "Dallas",
            "Galveston",
            "Houston",
            "Burlington",
            "Norfolk",
            "Richmond",
            "Seattle",
            "Adelaide",
            "Melbourne",
            "Calgary",
            "Edmonton",
            "Winnipeg",
            "London",
            "Toronto",
            "Christchurch",
            "Hamilton"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "Australia",
            "Australia",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "New Zealand",
            "New Zealand"
      ],
      "LocationFacility": [
            "University of Southern California University Hospital",
            "University of California, San Francisco",
            "Western States Clinical Research",
            "Clinical Research of West Florida",
            "Borland-Groover Clinic",
            "Shafran Gastroenterology Center",
            "Atlanta Gastroenterology Associates",
            "University of Chicago Medical Center",
            "Carle Clinic Association",
            "Indiana University Medical Center",
            "Cotton-O'Neil Clinical Research Center",
            "University of Kentucky Hospital",
            "University of Louisville Hospital",
            "Gulf Coast Research",
            "University of Maryland, Baltimore",
            "National Institutes of Health",
            "Chevy Chase Clinical Research",
            "Massachusetts General Hospital",
            "Brigham and Womens Hospital",
            "Clinical Pharmacology Study Group",
            "Center for Clinical Studies",
            "Center for Digestive Health",
            "University of Minnesota Hospital",
            "St Louis Center for Clinical Studies",
            "Dartmouth Hitchcock Medical Center",
            "Weill Cornell Medical College",
            "Mount Sinai School of Medicine",
            "Rochester Institute for Digestive Diseases",
            "Rochester General Hospital",
            "University Hospital and Medical Center",
            "Charlotte Gastroenterology and Hepatology",
            "Pinehurst Medical Clinic",
            "Wake Forest University",
            "Gastroenterology United of Tulsa",
            "Options Health Research",
            "Allegheney Center for Digestive Health",
            "University of Pittsburgh",
            "Gastroenterology Center of the Midsouth",
            "Nashville GI Specialists",
            "Vanderbilt University Medical Center",
            "Baylor University Medical Center",
            "University of Texas Medical Branch",
            "University of Texas Health Science Center",
            "University of Vermont",
            "Digestive and Liver Disease Specialists",
            "McGuire Research Institute",
            "Seattle Gastroenterology Associates",
            "Royal Adelaide Hospital",
            "Royal Melbourne Hospital",
            "University of Calgary",
            "University of Alberta Hospital",
            "Health Science Centre",
            "London Health Sciences Centre",
            "Mount Sinai Hospital",
            "University of Otago",
            "Waikato Hospital"
      ],
      "LocationState": [
            "California",
            "California",
            "Colorado",
            "Florida",
            "Florida",
            "Florida",
            "Georgia",
            "Illinois",
            "Illinois",
            "Indiana",
            "Kansas",
            "Kentucky",
            "Kentucky",
            "Louisiana",
            "Maryland",
            "Maryland",
            "Maryland",
            "Massachusetts",
            "Massachusetts",
            "Massachusetts",
            "Michigan",
            "Michigan",
            "Minnesota",
            "Missouri",
            "New Hampshire",
            "New York",
            "New York",
            "New York",
            "New York",
            "New York",
            "North Carolina",
            "North Carolina",
            "North Carolina",
            "Oklahoma",
            "Oklahoma",
            "Pennsylvania",
            "Pennsylvania",
            "Tennessee",
            "Tennessee",
            "Tennessee",
            "Texas",
            "Texas",
            "Texas",
            "Vermont",
            "Virginia",
            "Virginia",
            "Washington",
            "South Australia",
            "Victoria",
            "Alberta",
            "Alberta",
            "Manitoba",
            "Ontario",
            "Ontario"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "90033",
            "94115",
            "80033",
            "33765",
            "32256",
            "32789",
            "30342",
            "60637",
            "61801",
            "46202",
            "66606",
            "40536",
            "40202",
            "70808",
            "21201",
            "20892",
            "20815",
            "02114",
            "02115",
            "01610",
            "48124",
            "48098",
            "55455",
            "63128",
            "03756",
            "10028",
            "10029",
            "14607",
            "14621",
            "11794",
            "28207",
            "28734",
            "27157",
            "74135",
            "74137",
            "15212",
            "15213",
            "37138",
            "37205",
            "37232",
            "75246",
            "77555",
            "77030",
            "05401",
            "23502",
            "23249",
            "98133",
            "T2N 4N1",
            "T6G 2X8",
            "R3A 1R9",
            "N6A 5A5",
            "M5G 1X5"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [
            "NCT00609232"
      ],
      "OfficialTitle": [
            "A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "CRD 603"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Mahboob Rahman, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "September 15, 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Disease remission (CDAI at or below 150)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "28 days"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Disease improvement (Reduction by at least 100 points in CDAI)",
            "Improvement in quality of life (IBDQ)",
            "Reduction in number of draining fistulas"
      ],
      "SecondaryOutcomeTimeFrame": [
            "28 days",
            "28 days",
            "28 days"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "September 17, 2007"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 4, 2007"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "May 30, 2007"
      ],
      "StudyFirstSubmitQCDate": [
            "May 31, 2007"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}